My Companies
Notification
Account
Log Out
Login
SEC under CDSCO approved grant of marketing authorization for OERIS, Shilpa's extended-release ondansetron injection 100 mg/mL, claimed world's first single-dose 120-hour CINV protection after successful Phase III; patent protected in India till 2039, commercial India launch planned after final CDSCO authorization.
Shilpa Medicare Subsidiary FTF Pharma Enters Insolvency Resolution Process
Shilpa Medicare Inks Nivolumab Biosimilar Co-Development Deal with Finland's Orion
Shilpa Medicare Commissions Integrated ADC Drug Substance GMP Manufacturing Facility